Skip to main content

Table 3 Diagnostic power of AFP to discriminate patients with HCC from patients with cirrhosis in different three staging systems

From: A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

Classification AUC Sens% Spe% PPV% NPV% AC%
Number of nodules (n, %)
 Single (67, 43.2%) 0.71 22 100 100 53 58
 Multiple (88, 56.8) 0.74 31 100 100 52 60
Macrovascular invasion (n, %)
 Absent (141, 91%) 0.74 25 100 100 38 48
 Present (14, 9%) 0.65 50 100 100 90 91
Size of nodules (n, %)
 <2 (48, 31%) 0.72 13 100 100 63 65
 >2 (107, 69%) 0.75 33 100 100 49 59
BCLC stage (n, %)
 0-A (109, 70.3%) 0.71 19 100 100 41 48
 B (46, 29.7) 0.8 52 100 100 75 80
CLIP stage (n, %)
 0-1 (122, 79%) 0.69 17 100 100 39 45
 2-3 (33, 21%) 0.88 63 100 100 82 86
Okuda stage (n, %)
 Stage I (117, 75.5%) 0.67 23 100 100 41 50
 Stage II (38, 24.5%) 0.89 39 100 100 70 75